Current Clinical Laboratory Biosafety Practices

Michael Pentella, PhD, D(ABMM)
University of Iowa, Clinical Professor
State Hygienic Laboratory, Director

Presentation objectives

- Understand the needs of clinical laboratories
- Review the clinical laboratory biosafety survey regarding biosafety practices
- Describe the activities of the APHL Biosafety and Biosecurity Committee on behalf of both clinical and public health laboratories

Evolving Biosafety by the Decades

1880's

1920's

1950's

Biosafety practices evolved mostly driven by regulatory requirements

Despite improvements in laboratory safety, including specialized training, advances in laboratory design, and the use of personal protective equipment, laboratoryacquired infections still occur.






2000's




Recent Lab Acquired Infections



Maryland researcher acquired *Burkholderia mallei* in the lab diagnosed with glanders



California, 17 clinical lab scientists exposed to *Burkholderia* pseudomallei, all received antibiotics, no illnesses



New Agent:
Pennsylvania, Lab
acquired zika virus
through needlestick

1988 2000 2002

2003 2006

2016

California, clinical lab scientist dies after lab exposure to Neisseria meningitidis MMWR 1991



New Agent: Iowa, PHL microbiologist acquired West Nile virus through a scalpel wound when handling a dead crow





Indiana and Minnesota, clinical lab scientists acquired Brucellosis after lab exposures, unrelated strains



Historically: Safety has been a concern

Example: First College of American Pathologists checklist in 1965







Past College of American Pathologist Inspection and Accreditation Newsletters

March 1973

a. Departmentalization: Questions regarding the physical facilities, safety, personnel, procedures, quality control and instrumentation have been written to cover each department.

Winter 1981

A new safety checklist has been added to each technical manual. This is modified for each section, but most of it repeats the questions. The redundancy is regrettable, but necessitated by our highly variable inspection chores.



Then – Summer 1974 Note – no "dump picking"

DISPOSAL OF CONTAMINATED WASTES

The following recommendations were abstracted from the 4th quarter CDC report on Nocosomial Infections.

- 1. Specific policies should be developed for the handling and method of disposal of all hazardous materials.
- 2. Hazardous materials should be either carefully flushed down the sewage system or doubly packaged in impervious plastic bags. (Ed. note: OSHA regulations require such packages to be clearly marked as to type of hazard and who to notify in case of accidental spillage).
- 3. Bacteriologic wastes should be either autoclaved or incinerated. (Ed. note: Flooding of plates with disinfectant prior to disposal is also recommended).
- 4. Blood specimens should be either carefully poured into the sewage system or double bagged and incinerated.
 - 5. Pathology wastes should be double bagged and incinerated.
 - 6. Solid materials which could cause injury (needles, scalpel blades, broken glassware) should be disposed of in rigid containers. Contaminated and potentially contagious materials should be either autoclaved, or double bagged and incinerated.
 - 7. Non burnables may be either ground up and flushed into the sewer or disposed of into a sanitary land fill. Finally, scavenging or "dump picking" should not be permitted in any dumps receiving hospital wastes.



Then – BSC Fall 1975 – I&A newsletter

DISINFECTION OF BIOLOGIC SAFETY CABINETS

Ventilation followed by UV radiation before and after handling cultures is recommended for day to day maintenance, but it is not adequate for thorough decontamination of a system. (UV light doesn't reach filters.) Effective decontamination of the entire system in situ can be achieved by means of gaseous fumigants, such as ethylene oxide, B. propiolactone,

formaldehyde or glutaraldehyde. The latter two are preferable since ethylene oxide may be explosive if combined with CO2 and B propiolactone is carcinogenic. Vaporization of about 30 cc of 10% formaldehyde per cubic feet in a sealed cabinet left to stand overnight is said to be effective. Ref: H.R. Barlow, "Safety in the Microbiology Laboratory", Soc. for Applied Bacteriology. Tech. Series No. 6. Academic Press.



Then – Exposure Fall – 1981 CAP I&A newsletter

LABORATORY ACQUIRED INFECTIONS

Many of us continue to treat safety precautions in cavalier fashion. Some laboratories, unfortunately, "smarten up" only around inspection time. There is always a lurking killer and disbelievers are urged to read Fatal Salmonellosis Originating in a Clinical Microbiology Laboratory, Blaser, M.J. and Lofgren, J.P. J Clin Microbiol 13:855-858, May 1981.



2019: Safety – Major Laboratory Concern

CAP Addresses Safety

LABORATORY GENERAL INDEX:

Safety policies, procedures and records

Bloodborne Pathogens

Other Infectious Hazards

Fire Prevention and Protection

Electrical Safety

Chemical Safety

Compressed Gases

Radiation Safety

Environmental Safety

Other Hazards

Waste Disposal

MICROBIOLOGY CHECKLIST:

Biosafety

Laboratory Safety

CLIA Addresses Safety:

§493.1101, §493.1254 (a)(1)(2), §493.1407 (e)(2, 10,

11 & 12), §493.1445 (e) (11, 12, & 13)

Safety procedures must be established

Facilities – space, ventilation, and utilities meet the

testing needs.

Director – ensure that the testing environment is

safe



Biosafety GEN.74000, 74100, and 74200


- Infection Control policies must comply with OSHA Bloodborne Pathogens Standard
- Engineering and Work Practice Controls to reduce or eliminate exposure to bloodborne pathogens



- Specific PPE requirements, with exception of glove use, is determined by facility and based on "reasonably anticipated exposure"
- Records of training/instructions for use of PPE
- If tasks are identified and required PPE stipulated, practice must match policy


GEN.74250

- Hand cleaning
 - Personnel remove gloves, use an effective antimicrobial method
 - After manipulating biological samples
 - After each patient contact



GEN.74700, 74800, 74900

- Employer must educate staff on risk of BBP and offer Hepatitis B Vaccinations
- Exposure Control Plan Viral (HIV, HBV, HCV)
 - Testing of the source patient, with consent
 - Records of the evaluation of the healthcare worker
 - Appropriate prophylaxis and follow-up
 - Reporting, as required by law
- TB Exposure Plan
 - Written plan
 - Include exposure determination at defined intervals; can use riskbased approach
 - Includes the use of NIOSH-approved, fit-tested, filter respirators
 - Defined engineering and work practice controls



GEN.75000

Sterilizing Device Monitoring

- Frequency must be defined
- Biologic or chemical indicator
- Test performed under conditions that simulate actual use

GEN.77900

Biohazard Disposal Containers



- All infectious wastes are discarded in labeled containers
- Container must be leak proof with solid tightfitting covers
- Compliant with local regulations

MIC.19035, 19010

- MIC.19035 Safe
 Specimen Processing
 - Written policies and procedures
 - Tight sealing containers
 - Spills
 - PPE
- BenchtopDecontamination
 - Daily, with records



MIC.18968, 18976

- Agents of Bioterrorism
 - policies and procedures for recognition of microorganisms likely to be used as biological weapons
 - safe handling of potential agents – use of BSC, not using automated instruments for identification

Bioterrorism Response Plan

 must define the laboratory's role and responsibilities



MIC.19840, 20520

- Biological Safety
 Cabinet
 - available per biosafety level
 - maintained
 - certified annually, with records
 - meets minimum requirements for testing performed



MIC.19060, 19160

- Biosafety Levels
 - In accordance with current recommendations for working with different organisms
 - Engineering
 - Equipment
 - Containment
 - Work practices



OSHA Laboratory Safety Guidance 2011

- General Duty Clause, employers "shall furnish to each of his employees employment and
 a place of employment which are free from recognized hazards that are causing or likely
 to cause death or serious physical harm to his employees."
- **Bloodborne Pathogens standard (29 CFR 1910.1030)**, including the Needlestick Safety and Prevention Act of 2001, requires employers to protect workers from infection with human bloodborne pathogens in the workplace.
- Personal Protective Equipment (PPE) standard (29 CFR 1910.132) requires that employers provide and pay for PPE and ensure that it is used.
- Respiratory Protection standard (29 CFR 1910.134) requires that a respirator be provided to each worker when such equipment is necessary to protect the health of such individual.
- Hand Protection standard (29 CFR 1910.138) requires employers to select and ensure that workers use appropriate hand protection when their hands are exposed to hazards.

Historical Events Triggering Regulations

Biosecurity Guidelines and Regulations

After 2001, as a result of Bioterrorism Preparedness training, many clinical and public health labs are trained on safety. WORLD Brucellosis exposure at RISK Horsepox Texas A&M virus synthesis Federal Burea of Investigation Nonproliferation WH Policy Studies Process on Biotechnology Risks 1970s 1990s 2010s 2000s Biodefense Strategy **BWC** Gain of USA **NSABB FESAP** Function PATRIOT Recombinant Policy Act Gene **DNA Guidelines** Bioterrorism Select Agent synthesis Federal Anti-terrorism Program P3CO Strengthened guidance Guidance Act Established Select Agent on Dual Use Biosafety Regulations Life Guidelines Further Strengthened Sciences

Research

Select Agent Regulations

2014 Clinical Lab Response to Ebola

- Labs reluctant to test specimens from suspect patients
- Unfamiliar with risk assessment process and had not adopted biosafety competencies
- Only considered risk of emerging infectious agent to the clinical microbiology lab section, not chemistry, hematology, anatomic path
- Some instrument manufacturers refuse to service instruments used to test patient's with ebola specimens


Cooperative Agreement Overview

- May 2015: APHL was awarded a \$2.2 million CoAg by the Centers for Disease Control and Prevention (CDC) for Domestic Laboratory Biosafety for Ebola and other Highly Infectious Diseases.
- Funded for three years (May 2015 May 2018)
 Received a one year extension to 2019
- Linked to the \$21 million funding opportunity awarded to 62 PHLs via the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Ebola Supplemental project B-Enhanced Laboratory Biosafety and Biosecurity Capacity.

Biosafety and Biosecurity Committee Charge

- Serve as Subject Matter Expert (SME), providing guidance and support for public health labs (PHLs)
- Coordinate national efforts to improve biosafety in PHLs and support outreach to clinical laboratories





APHL Major Biosafety and Biosecurity Accomplishments

Biosafety Community of Practice

- Two Collaborate Platforms (250+)
- BSO Peer Network (50+ PHLs Paired)
- Biosafe360 Program (200+)
- Technical Skills Building Workshops/ Webinars (750+)
- Leadership Development Workshop Series (34 PHLs with 37 BSOs)

Biosafety and Biosecurity Committee

- Subject Matter Expertise
- Consultations with PHIs

Biosafety and Biosecurity Partners Forum


- Awareness at the National Level
- Clinical Laboratory Biosafety
 - Biosafety Practices and Needs in Clinical Laboratories Survey
 - Biosafety Forums: Public Health Laboratory Outreach, Clinical Laboratory Engagement and Needs

CULTURE OF BIOSAFETY CHANGE

- Hire Biosafety Officers
- Provide Training and Tools for BSOs (Risk Assessments, Workshops and Biosafety Checklists)
 - Build a Community of Practice
 - Provide training and resources for Clinical Labs
 - Continue assisting PHL and Clinical Labs
















Introductory Memorandum: Recruiting Biosafety Officers

The Association of Public Health Laboratories (IAPH) developed the enclosed competency-based
Bloosafety Officer Public Description (Pol Templete to social state and local public laboratories with
their recruitment efforts. Utilizing funds from the Centers for Disease Control and Prevention (DCQ)

Individuals and all advantors Canastry for Mericina Disease (TIC Concertains Aerenter and If I

The following may vary with the agency electing to use the Biosafety Officer PD Template: position titl

APHI, thanks the Workforce Development Public Health Laboratory Competency Implementation

aphl.org/biosafety







Building Biosafety Awareness

- Advocacy: need continued federal funding
- Connection with Academia: Biosafety Curricula
 - Kirkwood Community College





Partners Forum: A collaboration for culture change

- APHL led collaboration between Federal and private sector partners connected with clinical laboratories engaged in evaluating and improving PH and clinical lab biosafety and biosecurity practices in the U.S.
- Convene an annual in person meeting (2016 and 2017) and 6 month follow up call
- Transitioning to the Clinical Laboratory Partners Forum



ABSA Was There!

Amer. Society Of Clinical Pathology

Amer. Biological Safety Assoc.

Amer. Assoc. For Clinical Chemistry

The Joint Commission

Amer. Assoc. Of Bioanalysts


Centers For Disease enters for Medicare & Medicaid Services

Centers for Medicare Amer. Society For Microbiology Food And Drug Administration

Clinical Laboratory Management Assoc.

Slide courtesy of Michael Marsico

Biosafety and Biosecurity Partners Forum




Laboratory Biosafety CollABorate Community

Clinical Laboratory Biosafety Risk Management Program Assessment Checklist



Disinfectant Webinar



Clinical Laboratory Survey

Slide courtesy of Michael Marsico



Partners Forum Activities


Beginning Challenges

- Reviewed state of biosafety in clinical labs
- Lack of familiarity with biosafety risk assessment process
- Unknown risk of new technology ex. MALDI-ToF

Future Activities

- Potential regulatory action by some organizations
- Adding additional biosafety items to checklists already in place
- Continue to promote biosafety awareness

Biosafety Roadmap for Clinical Labs



Biosafety Practices and Needs in Clinical Laboratories Survey

- Launched in June 2018
- Purpose: to determine needs in sentinel clinical laboratories as well as laboratories in facilities that were identified as Ebola Treatment Centers (ETCs) and Ebola Assessment Hospitals (EAHs) across the United States
- Estimated target audience of 5,000 laboratories: 489 laboratories responded
- 376 stated they were defined as a sentinel clinical laboratory
- 147 stated they identified an Ebola Assessment Hospital
- 21 stated they identified as an Ebola Treatment Center

Response by State

Responses ranged from

- A high 11% in Georgia and New York (54 laboratories each)
- A low of 0.2% in Alaska, Alabama, Colorado, Kentucky,
 Michigan, Nebraska, and New Mexico (1 laboratory each)



Does your institution have staff who are responsible for biosafety?



54.4%, No full time staff dedicated to biosafety but responsibility is allocated to multiple staff across all institutional laboratories




10%, No



34.7%, Yes, includes full time or part time

How many staff in your facility are currently certified in safe packaging/shipping of International Air Transport Association (IATA) Division 6.2 Category A Infectious Substances?


n	Total	Average	Median	Min	Max
489	2,743	6	4	0	100







9.2%, n = 45


Does your institution have a biosafety plan in place?






Have you developed safety-specific competencies for laboratory staff?






The majority were incorporation into their annual general competencies review. Other responses included laboratories were unaware of safety specific competencies and not being able to develop them due to time constraints

Are you aware of the following Competency Guidelines?







YES 55.2% N = 217 YES 44.7% N = 217

From May 2015 to May 2018, did your institution complete risk assessments?



YES = 56.4%

n = 276

Yes at least one = 37.4% 183

Yes - at least two = 19% (33)

Yes - other = 10.6% (52)

Annual risk assessments and general laboratory risk assessments or utilizing risk assessments and evaluating risks when conducting LPX.



NO = 32.9%

n = 161

Has your staff received training on the following topics: 100% - 95%

TOPIC	YES	N =	No	N =
Sharps Hazard	99.6%	487	0.4%	2
Bloodborne Pathogens	99.4%	486	0.6%	3
Personal Protective Equipment (PPE)	99.2%	485	0.8%	4
Spill Prevention, Control, and Countermeasure	97.5%	477	2.5%	12
Chemical Hazards	95.9%	469	4.1%	20

Has your staff received training on the following topics: 94%-90%

TOPIC	YES	N =	NO	N =
Biological Safety Cabinets (BSCs) and other Engineering Controls	92.6%	453	7.4%	36
BSL-2 safe practices (fundamentals of biological materials safety practices, excluding bloodborne pathogen training)	91.6%	448	8.4%	41
Regulated Waste Management	90.8%	444	9.2%	45
Emergency Management and Response	90.2%	441	9.8%	48
Continuous Quality Improvement (review, improvement, and implementation)	90.2%	441	9.8%	48

Has your staff received training on the following topics: 89%-30%

TOPIC	YES	N =	NO	N =
Certification in packaging/shipping of IATA Division 6.2 infectious substances (Category A)	89.4%	437	10.6%	52
Decontamination	87.5%	428	12.5%	61
Biological Risk Assessment	69.3%	339	30.7%	150
Select Agent Regulations	67.1%	328	32.9%	161
Biosecurity Plan	64.6%	316	35.4%	173
BSL-3 safety practices	44.4%	217	55.6%	272
Safe Handling and Use of Cryogenic Liquids	30.5%	149	69.5%	340

Additional training needs

TOPIC	0/	
Biosecurity Plan	% 16.2%	79
Select Agent Regulations	15.1%	74
Biological Risk Assessment	14.9%	73
Certification in packaging/shipping of IATA Division 6.2 infectious substances (Category A)	12.9%	63
BSL-3 safety practices	11.7%	57
Continuous Quality Improvement (review, improvement, and implementation)	9.4%	46
BSL-2 safe practices (fundamentals of biological materials safety practices, excluding bloodborne pathogen training)	7.8%	38

Additional training needs

TOPIC	%	n
Emergency Management and Response	7.4%	36
Decontamination	7.2%	35
Regulated Waste Management	5.1%	25
Safe Handling and Use of Cryogenic Liquids	4.1%	20
Chemical Hazards	3.9%	19
Biological Safety Cabinets (BSCs) and other Engineering Controls	3.3%	16
Spill Prevention, Control, and Countermeasure	2.0%	10
Personal Protective Equipment (PPE)	1.0%	5
Sharps Hazard	0.6%	3
Bloodborne Pathogens	0.6%	3

Training: What training materials do you use?

Public Health Laboratory Provided Training

67.7% n = 331

Self Developed Training

63.0% n = 308



Purchased training

32.5% n = 159

Other - CDC and CAP developed training materials and trainings offered through hospital and health care systems.

16.6% n = 81

What training mechanism(s) do you currently use?

Answer	%	n
In-Person/Classroom	65.6%	321
Online/Archived Webinar	58.1%	284
Online/Live Webinar	47.6%	233
Virtual Course	32.3%	158
Other - responses included hands-on drills, tabletop exercises and written procedures.	10.8%	53
Telephone (no web component)	4.5%	22

How do you identify biosafety training needs?

Answer	%	n
Accreditation/Certification checklist	71.6%	350
Gap risk assessment	41.1%	201
None, do not evaluate	11.5%	56
Other - individual staff competency assessments, review of public health laboratory resources, institutional safety inspections and site visits by consultants and public health laboratory staff, and mock drills and exercises.	11.2%	55

Briefly describe biosafety training needs for your facility and your plans to address those needs.

- Responses included training in the areas of packaging and shipping, risk assessments and proper personal protective equipment usage.
- Other responses included training needs in biosafety plans, biosafety competencies and regulatory requirements.
- Responses to address these needs included online and in-person courses available through public health laboratories, CDC and consultants.

What top three conferences would you or your colleagues attend to strengthen your biosafety knowledge, skills and abilities?

- The majority of responses included
 - American Society for Microbiology (ASM)
 Microbe,
 - CDC International Biosafety Symposium
 - American Biological Safety Association Annual Biosafety and Biosecurity Conference.



Connections with PHL

How satisfied are you with the services and support provided by your public health laboratory biosafety officer?

Answer	%	n
Very satisfied	30.4%	91
Satisfied	50.2%	150
Somewhat satisfied	17.4%	52
Unsatisfied	1.3%	4
Very unsatisfied	0.7%	2

Briefly describe your rating of the public health laboratory biosafety officer.

- The majority rated their public health laboratory biosafety
 officer very highly, stating that these staff are very
 knowledgeable and communicate regularly, sending pertinent
 information on available trainings and available at all times for
 questions.
- Respondents saw the site visits provided by the biosafety officers as very useful.
- Some respondents stated that they have not directly interacted with their public health laboratory biosafety officer as of yet and would like more involvement and information from their biosafety officers.

What are your needs of a public health laboratory biosafety officer?

- More guidance and communication around laboratory biosafety was needed specifically relevant information and trainings.
- Some respondents stated that more in-person communications and visits across the laboratory would be helpful.

Biosafety Forum: Public Health Laboratory Outreach, Clinical Laboratory Engagement and Needs

Focus: Discuss the current and unmet biosafety needs and challenges of both public health and clinical laboratories, define a successful outreach program and discuss solutions to enhance biosafety.



Biosafety Forums: Public Health Laboratory Outreach, Clinical Laboratory Engagement and Needs

Regional one day forums inviting clinical laboratories from a jurisdiction

Discuss the effectives of biosafety outreach programs and ongoing needs from public health labs and clinical labs

Forum locations: Minnesota Department of Health Public Health Laboratory, Hawaii State Laboratories Division, North Carolina State Laboratory of Public Health, California Department of Public Health State Public Health Laboratory





84 clinical laboratory representatives

28 hosting PHL representatives

12 local PHL representatives (CA forum)

5 APHL staff

6 CDC staff (5 DLS, 1 DPEI/ELC) 1 Retired LabCorp
Participant


Biosafety Forums Continued

Challenges and Needs: Training and Resources, Workforce, and Lack of a Dedicated BSO followed by Leadership Buy-In and Improvement in Workflow, Facilities, and their Infrastructure

Clinical Laboratory Prioritization of Needs







Lack Of A DEDUCATED & COMPRISE COMPRIME COMPRIANCE BUYINI ROUTE SUPPORT ROUTE LEAGURE SHE BUYING ACK OF BUSHELY RISK.



Training and Resources Needs Identified

- Risk Assessments
- Packaging and Shipping
- BSL-2&3 Practices

9a. If public health laboratory training was available to you at no cost, would you choose the following areas/ topics?

Ougation	Yes		
- Andrews	%	n	
Biological Risk Assessment	89.8%	439	
Biosecurity Plan	87.1%	426	
Certification in packaging/shipping of IATA Division 6.2 infectious substances	84.9%	415	
BSL-2 safe practices (fundamentals of biological materials safety practices, excluding bloodborne pathogen training)	80.8%	395	
Continuous Quality Improvement (review, improvement, and implementation)	76.5%	374	
Select Agent Regulations	76.3%	373	
Emergency Management and Response	75.3%	368	

9. Has your staff received training on the following topics?

Quarties	Ye	s
Question	%	n
Sharps Hazard	99.6%	487
Bloodborne Pathogens	99.4%	486
Personal Protective Equipment (PPE)	99.2%	485
Spill Prevention, Control, and Countermeasure	97.5%	477
Chemical Hazards	95.9%	469
Biological Safety Cabinets (BSCs) and other Engineering Controls	92.6%	453
BSL-2 safe practices (fundamentals of biological materials safety practices, excluding bloodborne pathogen training)	91.6%	448
Regulated Waste Management	90.8%	444
Emergency Management and Response	90.2%	441
Continuous Quality Improvement (review, improvement, and implementation)	90.2%	441
Certification in packaging/shipping of IATA Division 6.2 infectious substances (Category A)	89.4%	437
Decontamination	87.5%	428
Riological Risk Assessment	69.3%	339
Select Agent Regulations	67.1%	328
Biosecurity Plan	64.6%	316
BSL-3 safety practices	44.4%	217
Safe Handling and Use of Cryogenic Liquids	30.5%	149

Unmet Needs and Issues across Laboratories

- Dedicated Biosafety Officers
- Clinical laboratory biosafety practices
- Lack of biosafety buy in from leadership
- Biosafety not seen as a priority across laboratories
- Hands on training
 - Risk Assessments
- Mentorships across laboratories
- Biorisk Management Workshop invited over 40 clinical laboratories from across the state of Florida to attend





Unmet Needs and Issues across Laboratories

- Dedicated Biosafety Officers
- Clinical laboratory biosafety practices
- Lack of biosafety buy in from leadership
- Biosafety not seen as a priority across laboratories
- Hands on training
 - Risk Assessments
- Mentorships across laboratories




Good News! Biosafety has gotten attention in the last several years...





sealed vials with freeze-dried smallpox virus were in July 2014 in a storage room at the National Insti of Health (NIH) in Bethesda MD USA that 42 years had been turned over to the FDA



Concerns for the Future

- Sustainable Federal Funding
- BSOs leaving for other biosafety careers for private/academic institutions
 - Other bench role duties at PHL
 - Losing subject knowledge
- Relationships built across laboratories
- Are we prepared for the next Ebola?

10. Based on the training and knowledge of your laboratory staff, do you believe they are prepared to respond to an emerging threat comparable to Ebola Virus Disease?

Answer	%	n
Yes	60.5%	296
No - Please provide a brief explanation as to why staff are not prepared to respond to an emerging threat	39.5%	193

Explanations included lack of specific knowledge and training on how to respond to an emerging threat, institutions not having the proper resources including facilities, equipment and staff necessary, and lack of documented laboratory procedures. Individual responses are on file with APHL.



New Instruments another area of need

TABLE 1 Viability of BT agents following MALDI-TOF sample preparation

	No. of tubes with growth using indicated sample preparation method/no. tested								
	Direct colony		On-plate formic acid			Tube extraction			
Organism(s)	Target	Spot + Matrix	Spot	Target	Spot + Matrix	Spot	Target	Spot + Matrix	Spot
Bacillus anthracis	3/5	5/5	5/5	1/5	5/5	5/5	0/5	1/5	5/5
Burkholderia thailandensis	0/5	5/5	5/5	0/5	5/5	5/5	0/5	0/5	5/5
Clostridium botulinum/Clostridium perfringens	1/5	1/5	3/5	1/5	0/5	2/5	0/5	1/5	4/5
Francisella tularensis	1/5	2/5	4/5	1/5	2/5	5/5	0/5	1/5	5/5
Yersinia pestis	0/4	3/4	4/4	1/4	4/4	4/4	0/4	0/4	3/4
Brucella abortus	0/4	3/4	4/4	1/4	4/4	4/4	0/4	0/4	3/4
Total	5/28	19/28	25/28	5/28	20/28	25/28	0/28	3/28	25/28

Rudrik et al. JCM. Safety and Accuracy of MALDI for identification highly pathogenic organisms. October 2017



Ideas for the Future

- Identify Solutions for the Needs Addressed
 - Training Needs
 - Workforce/Biosafety Curriculum
 - Biosafety Culture/Buy-In
 - Connections with Physicians and Nurses
 - Biosecurity
- Streamlined Approach towards Biological Risk Assessment Training



Transforming biosafety into a quantitative practice

- We need evidence based data to as the basis for recommendations
- Risk assessments identify mitigation needs but there is no data on which to base the mitigation selected
 - Ex. Risk of aerosols from some lab procedures
 - Ex. What is the benefit of PPE in certain testing circumstances
- Data on the containment effectiveness of equipment and laboratories are scarce and fragmented.
- The tendency is to over protect which leads some to disregard the recommendation
- Using evidence-based data will enhance the effectiveness of biosafety measures as well as compliance with these measures

Future Vision

- Evidence based data to support decisions
- Collection of data on human reliability
- Collection of data on biosafety incidents
- Develop mathematical models to support further development of knowledge of biosafety, to detect gaps in our knowledge, and to support the development and evaluation of new biosafety measures

Biosafety in clinical labs at a crossroads

- Will the ebola experience have resulted in lasting changes in biosafety in the clinical labs?
 - Through CDC and APHL efforts many more labs recognize the importance of biosafety
 - There are limited requirements for biosafety in clinical labs.
 - Through the APHL Partners Forum,
 other organizations are considering
 changes that will keep biosafety in the forefront .



Thank you for your attention!

Questions?

